Cambridge Biotech submits HIV urine data to FDA
This article was originally published in Clinica
Results of a clinical trial of Cambridge Biotech's urine-based confirmatory Western blot test have been submitted to the FDA. The kit is intended as a specific supplemental test on urine samples which are repeatedly reactive to Calypte Biomedical's Sentinel urine EIA screening test for HIV. Cambridge Biotech, a wholly-owned subsidiary of bioMerieux Vitek, manufactures the Western blot test for Calypte Biomedical.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.